BI's prior Pradaxa use provides insufficient anticoagulation during PCI in CHD patients
This article was originally published in Scrip
Executive Summary
Using a short course of Boehringer Ingelheim’s oral direct thrombin inhibitor, Pradaxa (dabigatran), prior to percutaneous coronary intervention (PCI) does not provide sufficient anticoagulation during the elective procedure in stable coronary heart disease (CHD) patients as compared with unfractionated heparin (UFH), according to Phase IIa study.